Participated · Seed · Mar 2026

Excalipoint Therapeutics is a clinical-stage biotechnology company focused on discovering and developing T-cell engager (TCE) therapies for oncology and immunology indications. Its pipeline includes tri- and multi-specific antibody programs such as EXP011 (CTM012) targeting DLL3/CD3/4-1BB—entered Phase I/II with first patient dosed in October 2025—EXP012 (CTM013) targeting CDH17/CD3/4-1BB, and additional programs (EXP016, EXP017, EP101, EXP015) built on its TOPAbody, Immune Shield, and Pro-TCE platform technologies. The company is led by CEO Lei Fang and CFO Jielun Zhu. Following the $68.7M Seed raise, Excalipoint intends to use the funds to advance its proprietary platforms and progress its pipeline programs through clinical development.

Participated · Series C · Jun 2025

Arima Genomics leverages whole‑genome sequence and structural information to provide comprehensive, clinically actionable cancer therapy selection insights. Its proprietary platform captures how DNA is organized inside the nucleus, uniting chromatin architecture with sequence data in a single readout that uncovers gene fusions and rearrangements missed by other tests. The technology is already reaching patients through the company’s CLIA‑certified Aventa clinical testing laboratory in Orlando, Florida. Under new leadership, Arima plans to build on a decade of discovery‑driven research and launch a focused pipeline of clinical assays to expand the platform’s impact. The company is strengthening its focus on transforming oncology testing and accelerating clinical expansion. Arima is headquartered in Carlsbad, California. Arima Genomics, based in San Diego, develops 3D genomics technologies that connect DNA sequence and structural data to reveal biological insights that linear sequencing misses. Its products preserve and present the structural organization of the genome to drive discovery in genome biology and human health. The company’s solutions are used across applications including cancer, neurobiology, immunology, and translational medicine, and support development and optimization of approaches such as cell- and gene-based therapies and precision oncology research. Arima reports more than 600 global customers and has been cited in over 200 peer-reviewed studies. The company says it will expand its product portfolio and bioinformatics capabilities and scale operational and commercial capacity worldwide. Investors backing the company include both new and existing strategic and VC partners such as Genetron Health, Agilent Technologies, and Vectr Ventures. Arima Genomics builds research tools centered on its Arima HiC platform to enable analysis of genome sequence together with 3D genome structure. The company plans to expand commercial efforts and to develop new applications for the HiC platform, including adding structural analysis capabilities to conventional chromatin immunoprecipitation via HiChIP. Arima is also developing new products such as smooth-coverage HiC for gap-less de novo assemblies and population sequencing. The financing will support scaling of operations and enhancements to customer service and support. Since its initial product launch in 2018, Arima reports rapid customer and revenue growth. The company frames its technology as accelerating understanding of genome sequence and structure toward roles in human health and disease.

Participated · Series A · Jan 2024

ZWI Therapeutics develops protein therapeutics using a proprietary, patented polymer called polycarboxybetaine to create protein‑polymer conjugates intended as alternatives to PEG‑conjugated drugs. In preclinical animal models, its polycarboxybetaine conjugates have shown consistently low or no immunogenicity and improved pharmacokinetics versus PEG conjugates, which the company expects will translate to enhanced clinical durability and safety. The platform is also applicable to nanoparticles and hydrogels, with hydrogels highlighted for cellular therapy use. ZWI’s lead candidate, ZWI‑001 (an uricase‑polycarboxybetaine conjugate), has demonstrated preclinical proof of concept for treating hyperuricemia in severe gout and the company is progressing toward filing an IND after receiving FDA INTERACT guidance on CMC, nonclinical, and clinical plans. ZWI intends to out‑license its technology to pharmaceutical partners for specific development programs. The company announced board additions and a new CEO concurrent with the financing.

Led · Series A · Jan 2024

Myrobalan Therapeutics is a preclinical-stage biotechnology company headquartered in Medford, Massachusetts, focused on developing orally bioavailable, brain-penetrant small-molecule therapies to restore brain function. The company targets key pathologies underlying CNS dysfunction, including demyelination and neuroinflammation, applying expertise in drug discovery and neurological processes. Its lead program, MRO-002, is a small-molecule antagonist of GPR17 designed to remove a block to myelin repair. Myrobalan is developing MRO-002 specifically for progressive multiple sclerosis with the goal of promoting remyelination. The company says its candidates are positioned to treat neurodegenerative diseases, demyelinating disorders, and conditions involving recovery from CNS injury. Recent grant support from the National Multiple Sclerosis Society will advance the program's preclinical and translational development. Myrobalan Therapeutics is a preclinical-stage biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet-need central nervous system (CNS) conditions. Its pipeline focuses on brain-penetrant remyelination and anti-neuroinflammation programs, including a lead CSF1R inhibitor program and a demyelination-targeting GPR17 program. The company applies deep knowledge of neurological processes and innovative drug discovery tools to create highly selective, brain-penetrant therapeutic candidates. Myrobalan completed a subsequent closing of its Series A, adding $9 million and bringing total Series A funding to $33 million. The new capital is intended to advance the CSF1R program through first-in-human clinical testing and to progress the GPR17 program through IND-enabling studies. The company is headquartered in Medford, Massachusetts and is advancing its pipeline with strategic support from renowned institutional co‑founders. Myrobalan develops orally available small‑molecule neurorestorative therapies targeting demyelination and neuroinflammation to restore neural function in high‑unmet‑need CNS diseases. Its lead programs include a GPR17 antagonist to promote remyelination, a CSF1R inhibitor to address demyelination and neuroinflammation, and an allosteric TYK2 inhibitor to reduce neuroinflammation. The company applies brain‑penetrant, highly selective chemistry and strategic drug‑discovery tools to create candidates positioned for chronic, tolerable oral dosing. Myrobalan plans to address a broad range of neurological conditions linked to these mechanisms, including MS, Alzheimer’s disease, ALS, and rare neurological diseases. The company emphasizes strong preclinical data and a strategic chemistry partnership to advance candidates toward the clinic. Myrobalan is headquartered in Medford, Massachusetts, and completed a $24 million Series A to fund advancement of its pipeline.

Participated · Series A · Oct 2023

弘正储能 focuses on energy storage technology innovation and product R&D, offering a full lineup of storage products centered on BMS, PCS, EMS and a智慧云 platform. The company builds a cloud-edge-terminal collaborative system to enable full sensing, intelligent diagnostics, coordinated control and smart operation & maintenance for storage plants. It applies AI, big data analytics and cloud technologies to digitalize energy assets and operations. 弘正储能 targets generation-side, grid-side and user-side scenarios with tailored products and technical solutions. The company (弘正储能（上海）能源科技有限公司) recently completed an A+ financing round worth several tens of millions of yuan led by Puhua Capital. Proceeds are earmarked for storage-solution R&D and promotion, systematizing its digital platform, and constructing an asset operation and maintenance platform. Hongzheng Storage develops green energy integrated applications and system solutions with a focus on energy storage technology innovation and product R&D. It offers a full series of storage products centered on BMS, PCS, EMS and a smart cloud platform. The company applies AI, big data and cloud technologies to build a cloud-edge-end collaborative system for full perception, intelligent diagnosis, collaborative control and smart O&M of storage stations. Hongzheng targets scenarios across the generation side, grid side and user side, providing tailored products and technical solutions. The company emphasizes continued technology innovation and product development. Financially, Hongzheng recently completed a nearly ¥100 million Series A financing led by Licheng Capital with Kaifeng Venture and other institutions participating.